MV BioTherapeutics
MV BioTherapeutics is a spin-off company of IRB - Institute for Research in Biomedicine (affiliated to USI) which was established in 2018, originally as MicroVaccines and later renamed MV BioTherapeutics. The innovative technology at the core of the company has been developed in the Grassi’s lab at IRB. The technology platform for the development of oral vaccines against intestinal infections, with the aim of addressing currently unresolved medical needs with high patient accessibility. The technology has been patent protected by the IRB and licensed to the spin-off. In 2017, Grassi took the initial project, called EXEAD, to the then StartCup Ticino (now Boldbrain), coming in second in the finals.
